@prefix : <http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix core: <http://purl.obolibrary.org/obo/uberon/core#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix pato: <http://purl.obolibrary.org/obo/pato#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix time: <http://www.w3.org/2006/time#> .
@prefix core1: <http://purl.obolibrary.org/obo/core#> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix uberon: <http://purl.obolibrary.org/obo/uberon#> .
@prefix subsets: <http://purl.obolibrary.org/obo/ro/subsets#> .
@prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#> .
@prefix OpenPVSignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl#> .
@base <http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia> .

<http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia> rdf:type owl:Ontology ;
                                                                            owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ,
                                                                                        mp: ;
                                                                            rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/255500/"^^xsd:anyURI ;
                                                                            rdfs:label "Vemurafenib and Thrombocytopenia"^^xsd:Literal ;
                                                                            owl:versionInfo "draft-v0.95-20211109"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
OpenPVSignal:Free_text_reporting_element rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


#################################################################
#    Data properties
#################################################################

###  http://purl.org/mp/citation
mp:citation rdf:type owl:DatatypeProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaConclusionContent
:ConclusionContent rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Conclusion ;
                   OpenPVSignal:has_content "The data provided in the case series strongly supports a signal for the association between vemurafenib and thrombocytopenia. The suggestion of a possible mechanism, although speculative, adds further support for the signal." ;
                   rdfs:label "Conclusion content" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaDiscussionContent
:DiscussionContent rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Discussion ;
                   mp:references :Ref.10 ,
                                 :Ref.11 ,
                                 :Ref.8 ,
                                 :Ref.9 ;
                   OpenPVSignal:has_content """Discussion
In this series of 28 ICSRs in which vemurafenib is associated with thrombocytopenia, one case met the criteria for a ‘certain’ causal relationship between the suspected drug and the reported ADR according to the WHO-UMC System for Case Causality Assessment.8 Four cases had sufficient evidence to suggest a ‘probable’ association and a further 14 cases could be considered ‘possible’.
These 19 cases are summarised in Table 1. Bony infiltration associated with metastatic malignant melanoma (the indication for 21 of the 23 cases in which this information was provided) should be considered a risk factor for thrombocytopenia in each of these cases.
Case 22 provides the strongest evidence in this series for a causal relationship between vemurafenib and thrombocytopenia in that it has a plausible time relationship to drug exposure, no alternative explanation for the ADR, a positive dechallenge and a positive rechallenge. The case concerns a 65 year old female with a history of end-stage renal disease, arterial hypertension and a previous DVT. Thrombocytopenia and anaemia developed 19 days after initiation of treatment with vemurafenib for melanoma, and pancytopenia with febrile neutropenia developed on day 22 of therapy. Platelets were transfused. Vemurafenib was stopped for six days, during which time the platelet count improved; vemurafenib was then reintroduced at half the original dose but three days later the platelet count had again dropped, consistent with a positive rechallenge.
Vemurafenib was stopped definitively and the platelet count returned to normal. Clinical investigations ruled out alternative explanations for the thrombocytopenia.
Cases 2, 3, 5 and 13 could be considered to have a ‘probable’ causal relationship. The time-to-onset (TTO) for three of these cases ranged from 15-29 days; TTO was not stated for the fourth case but other information provided in the report indicates that the reaction occurred between 6 and 10 weeks after starting vemurafenib. In each of these four cases vemurafenib was withdrawn and the thrombocytopenia resolved; in Case 2, the drug was subsequently restarted at a lower dose with no recurrence of the ADR. No other drugs were suspected in any of the four cases (in three cases vemurafenib was the only reported drug).
The remaining 14 cases shown in Table 1 could be considered to have a ‘possible’ causal relationship to vemurafenib. The time-to-onset for these 14 cases, where reported, ranged from 3 to 169 days. Two of the cases reported co-suspected medicines known to be associated with thrombocytopenia: piperacillin/ tazobactam (Case 17) and carvedilol, spironolactone (Case 20). The latter case also reported the combination analgesic caffeine/paracetemol/papaver somniferum latex as suspected, but it is not known to be associated with thrombocytopenia. Levetiracteam, which is known to be associated with thrombocytopenia, was listed as a concomitant medicine in Case 11. Among these 14 cases, three cases reported evidence of a positive dechallenge (Cases 7, 12 and 23), one of which subsequently restarted vemurafenib with no recurrence of thrombocytopenia (Case 23). Concurrent infections including pneumonia and urinary sepsis may have accounted for the thrombocytopenia in each of these cases, and Case 23 was also confounded by other medicines.
The remaining six cases (not shown in Table 1) lacked sufficient evidence to suggest a causal relationship between vemurafenib and thrombocytopenia. In Case 8, the patient received radiation therapy to the lumbar vertebrae one day prior to starting treatment with vemurafenib and the thrombocytopenia improved while treatment with vemurafenib continued; in Cases 9 and 16, the thrombocytopenia appears to have preceded treatment with vemurafenib, and in Cases 25, 29 and 30, the temporal relationship to other medicines provides a more plausible alternative explanation for the thrombocytopenia. Causality could not be assessed for the remaining three cases (Cases1, 4 and 10) due to a lack of information in the reports.
Vemurafenib acts on mutated B-RAF protein to inhibit the RAS-RAF-MEK-ERK intracellular signalling pathway in melanoma cells to prevent cell growth and proliferation. This same pathway is also present in haematopoietic progenitor cells and plays a role in haematopoietic cell differentiation,9,10 suggesting a possible mechanism by which vemurafenib might cause thrombocytopenia. Platelets (thrombocytes) are formed from megakaryocytes, which derive from the multipotential hematopoietic stem cell (HSC). The HSC gives rise to progressively committed progenitor cells, including the common myeloid progenitor (CMP) and the megakaryocyte- erythroid progenitor (MEP). MEPs in turn give rise to both megakaryocytic and erythroid cell lineages. Multiple transcription factors are involved in the differentiation of these MEPs to megakaryocytes, the most important of which is thrombopoietin (TPO). Binding of TPO to the TPO receptor on the MEP cell surface membrane activates the intracellular signaling protein Jak2, which in turn activates several intracellular signaling cascades, including the RAS-RAF-MEK- ERK cascade.11
Six of the cases shown in Table 1 include co- reported ADR terms that indicate a more widespread myelosuppression, rather than an isolated thrombocytopenia (Cases, 5, 11, 13, 18, 22 and 26). These co-reported terms are highlighted in bold in Table 1. Granulocytopenia has previously been signalled for vemurafenib (SIGNAL, issue 3, 2013) and neutropenia has since been added to the US, UK and EMA product information sheets, adding support to the notion that vemurafenib may affect the RAS-RAF-MEK- ERK cascade in haematopoietic cells. It is possible that all of these cases in which vemurafenib is associated with depression of various blood cell lineages may represent a spectrum of drug induced myelosuppression, possibly brought about through an effect on the RAS-RAF-MEK-ERK intracellular signalling pathway in haematopoietic progenitor cells.""" ;
                   rdfs:label "Discussion content" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaDr_Geraldine_Hill
:Dr_Geraldine_Hill rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Author ;
                   OpenPVSignal:has_first_name "Geraldine" ;
                   OpenPVSignal:has_last_name "Hill" ;
                   rdfs:label "Dr Geraldine Hill" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaIndicationAsAConfounder
:IndicationAsAConfounder rdf:type owl:NamedIndividual ,
                                  obo:OAE_0001182 ;
                         OpenPVSignal:refers_to_adverse_effect :melanoma ,
                                                               :thrombocytopenia ;
                         OpenPVSignal:has_content "Bony infiltration associated with metastatic malignant melanoma (the indication for 21 of the 23 cases in which this information was provided) should be considered a risk factor for thrombocytopenia in each of these cases. " ;
                         rdfs:label "Indication as a confounder" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaIntroductionContent
:IntroductionContent rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Introduction ;
                     mp:references :Ref.1 ,
                                   :Ref.2 ,
                                   :Ref.3 ,
                                   :Ref.4 ,
                                   :Ref.5 ;
                     OpenPVSignal:has_content """Vemurafenib is a serine-threonine protein kinase inhibitor that inhibits the kinase activity of mutated B-RAF protein. The RAS-RAF-MEK-ERK mitogen activated protein kinase (MAPK) cascade is an important cytoplasmic signalling pathway involved in the regulation of normal somatic cell proliferation. Mutations in the genes encoding components of this pathway have been associated with a number of human cancers.1 An activating mutation in the BRAF gene, which encodes the serine-threonine protein kinase B-RAF, has been found to be present in 40-60 percent of melanomas, most commonly the BRAF V600E mutation.2 Vemurafenib is indicated for the treatment of metastatic or unresectable melanomas that carry the BRAF V600E mutation. The recommended dose is 960 mg twice daily and it is currently available in 240 mg tablets.3 Vemurafenib has also been used off-label for other types of malignancy carrying the BRAF V600E mutation.
Thrombocytopenia is defined as a platelet count of less than 150 x 109/L (150 000 per μL). A grading system for thrombocytopenia has been developed by the United States National Cancer Institute in which platelet counts between 75 x 109/L and 150 x 109/L are classified as Grade 1, while platelet counts below 25 x 109/L are classified as Grade 4.4 Patients with platelet counts above 20 x 109/L are usually asymptomatic, but the risk of spontaneous mucocutaneous bleeding (gingival bleed, epistaxis, menorrhagia, petechiae and ecchymoses) and life- threatening, spontaneous intracranial hemorrhage or gastrointestinal bleeding increases rapidly with platelet counts below 10 x 109/L.
Thrombocytopenia in the context of metastatic malignancy may result from a number of causes including metastatic infiltration of the bone marrow, sepsis, disseminated intravascular coagulation (DIC), radiation and drugs. Drug- induced thrombocytopenia (DIT) is associated with many drugs and results from either decreased platelet production or increased platelet consumption. Decreased platelet production as a consequence of generalized myelosuppression is a relatively common adverse effect of many chemotherapeutic drugs, while selective suppression of megakaryocyte production leading to isolated thrombocytopenia has been associated with thiazide diuretics, alcohol and tolbutamide.
Increased platelet destruction is further categorized as either immune or non-immune: drug-induced immunologic thrombocytopenia (DITP) is associated with a large number of drugs (most notably heparin) and several immunologic mechanisms have been identified. Non-immune platelet destruction such as TTP-HUS (thrombotic thrombocytopenic purpura – haemolytic uraemic syndrome) occurs less commonly, in association with a small number of anti-neoplastic agents.5
""" ;
                     rdfs:label "Introduction content" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaLiteratureAndLabelling
:LiteratureAndLabelling rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Literature_information ;
                        mp:references :Ref.3 ,
                                      :Ref.6 ,
                                      :Ref.7 ;
                        OpenPVSignal:has_content "Thrombocytopenia is not listed as a possible ADR for vemurafenib in any of the sources that were checked, including the EMA6, UK Summary of Product Characteristics7 and the US FDA Product Label.3 Neutropenia is the only haematological ADR listed in the product information." ;
                        rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaMechanismOfVemurafenib
:MechanismOfVemurafenib rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Mechanism ;
                        mp:references :Ref.1 ,
                                      :Ref.2 ;
                        OpenPVSignal:has_content "Vemurafenib is a serine-threonine protein kinase inhibitor that inhibits the kinase activity of mutated B-RAF protein. The RAS-RAF-MEK-ERK mitogen activated protein kinase (MAPK) cascade is an important cytoplasmic signalling pathway involved in the regulation of normal somatic cell proliferation. Mutations in the genes encoding components of this pathway have been associated with a number of human cancers.1 An activating mutation in the BRAF gene, which encodes the serine-threonine protein kinase B-RAF, has been found to be present in 40-60 percent of melanomas, most commonly the BRAF V600E mutation.2" ;
                        rdfs:label "Mechanism of Vemurafenib" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaMechanismsOfInducingThrombocytopenia
:MechanismsOfInducingThrombocytopenia rdf:type owl:NamedIndividual ,
                                               OpenPVSignal:Adverse_Effect_Mechanism ;
                                      OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
                                      mp:references :Ref.5 ;
                                      OpenPVSignal:has_content """Thrombocytopenia in the context of metastatic malignancy may result from a number of causes including metastatic infiltration of the bone marrow, sepsis, disseminated intravascular coagulation (DIC), radiation and drugs. Drug- induced thrombocytopenia (DIT) is associated with many drugs and results from either decreased platelet production or increased platelet consumption. Decreased platelet production as a consequence of generalized myelosuppression is a relatively common adverse effect of many chemotherapeutic drugs, while selective suppression of megakaryocyte production leading to isolated thrombocytopenia has been associated with thiazide diuretics, alcohol and tolbutamide.
Increased platelet destruction is further categorized as either immune or non-immune: drug-induced immunologic thrombocytopenia (DITP) is associated with a large number of drugs (most notably heparin) and several immunologic mechanisms have been identified. Non-immune platelet destruction such as TTP-HUS (thrombotic thrombocytopenic purpura – haemolytic uraemic syndrome) occurs less commonly, in association with a small number of anti-neoplastic agents.5""" ;
                                      rdfs:label "Mechanisms of inducing Thrombocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient11
:Patient11 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 53 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient12
:Patient12 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 12" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient13
:Patient13 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 68 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 13" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient14
:Patient14 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 68 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 14" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient15
:Patient15 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 61 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 15" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient17
:Patient17 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 70 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 17" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient18
:Patient18 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 52 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 18" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient2
:Patient2 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 58 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient20
:Patient20 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 44 ;
           OpenPVSignal:has_gender "male" ;
           rdfs:label "Patient 20" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient22
:Patient22 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 65 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 22" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient23
:Patient23 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 56 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 23" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient24
:Patient24 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 64 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 24" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient26
:Patient26 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 38 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 26" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient27
:Patient27 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 37 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 27" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient28
:Patient28 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 38 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 28" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient3
:Patient3 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 66 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient5
:Patient5 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 51 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient6
:Patient6 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 53 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPatient7
:Patient7 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 58 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaPossibleMechanismOfVemurafenibInducingThrombocytopenia
:PossibleMechanismOfVemurafenibInducingThrombocytopenia rdf:type owl:NamedIndividual ,
                                                                 OpenPVSignal:Adverse_Effect_Mechanism ;
                                                        OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
                                                        mp:references :Ref.10 ,
                                                                      :Ref.11 ,
                                                                      :Ref.9 ;
                                                        OpenPVSignal:has_content "Vemurafenib acts on mutated B-RAF protein to inhibit the RAS-RAF-MEK-ERK intracellular signalling pathway in melanoma cells to prevent cell growth and proliferation. This same pathway is also present in haematopoietic progenitor cells and plays a role in haematopoietic cell differentiation,9,10 suggesting a possible mechanism by which vemurafenib might cause thrombocytopenia. Platelets (thrombocytes) are formed from megakaryocytes, which derive from the multipotential hematopoietic stem cell (HSC). The HSC gives rise to progressively committed progenitor cells, including the common myeloid progenitor (CMP) and the megakaryocyte-erythroid progenitor (MEP). MEPs in turn give rise to both megakaryocytic and erythroid cell lineages. Multiple transcription factors are involved in the differentiation of these MEPs to megakaryocytes, the most important of which is thrombopoietin (TPO). Binding of TPO to the TPO receptor on the MEP cell surface membrane activates the intracellular signaling protein Jak2, which in turn activates several intracellular signaling cascades, including the RAS-RAF-MEK-ERK cascade.11" ;
                                                        rdfs:label "Possible mechanism of vemurafenib inducing thrombocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.1
:Ref.1 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Davies H, , Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54." ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.10
:Ref.10 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "Hsu CL, Kikuchi K and Kondo M. Activation of mitogen-activated protein kinase kinase (MEK)/ extracellular signal–regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment. Blood 2007;110(5):1420-8." ;
        rdfs:label "Ref.10" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.11
:Ref.11 rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Bibliographic_reference ;
        OpenPVSignal:has_content "11.   Geddis AE, Megakaryopoiesis. Seminars in hematology 2010;47(3):212-9." ;
        rdfs:label "Ref.11" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.2
:Ref.2 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Roberts PJ, Der CJ. Targeting the Raf-MEK- ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26(22):3291-310." ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.3
:Ref.3 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "US Food and Drug Administration. Zelboraf Label (Nov 2014) http://www.accessdata.fda. gov/drugsatfda_ docs/label/2014/ 202429s006lbl.pdf. Accessed: 3 March 2015." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.4
:Ref.4 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010, U.S. Department of Health and Human Services" ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.5
:Ref.5 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Visentin GP, Liu CY. Drug Induced Thrombocytopenia. Hematology/oncology clinics of North America 2007;21(4):685-96." ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.6
:Ref.6 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "European Medicines Agency, Zelboraf : EPAR - Product Information http://www.ema.europa. eu/docs/en_GB/ document_library/EPAR_-_Product_Information/ human/002409/WC500124317.pdf. Accessed: 3 March 2015." ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.7
:Ref.7 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Electronic Medicines Compendium UK. Zelboraf 240 mg film-coated tablets http://www.medicines.org.uk/emc/medicine/26056. Accessed 3 Mar 2015." ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.8
:Ref.8 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. [pdf] 2012 [cited 2015 3 March] http://www.who-umc.org/Graphics/ 26649.pdf." ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaRef.9
:Ref.9 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Chung E, Kondo M. Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. Immunol Res. 2011;49(1-3):248-68." ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport11
:Report11 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :anaemia ,
                                                :leukopenia ,
                                                :thrombocytopenia ;
          OpenPVSignal:refers_to_concomitant_drug :levetiracetam ,
                                                  :omeprazole ;
          OpenPVSignal:refers_to_patient :Patient11 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:time_to_onset :TimeToOnset11 ;
          OpenPVSignal:refers_to_outcome_after_action "death" ;
          rdfs:label "Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport12
:Report12 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :blackEyeHaemorrhage ,
                                                :bronchitis ,
                                                :thrombocytopenia ;
          OpenPVSignal:refers_to_patient :Patient12 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:time_to_onset :TimeToOnset12 ;
          OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
          OpenPVSignal:refers_to_outcome_after_action "recovering" ;
          rdfs:label "Report 12" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport13
:Report13 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :haemorrhageNos ,
                                                :leukopenia ,
                                                :thrombocytopenia ;
          OpenPVSignal:refers_to_patient :Patient13 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:time_to_onset :TimeToOnset13 ;
          OpenPVSignal:has_evaluation "Probable" ;
          OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
          OpenPVSignal:refers_to_outcome_after_action "recovering" ;
          rdfs:label "Report 13" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport14
:Report14 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
          OpenPVSignal:refers_to_patient :Patient14 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:time_to_onset :TimeToOnset14 ;
          OpenPVSignal:has_evaluation "Possible" ;
          OpenPVSignal:refers_to_dechallenge_outcome "unknown" ;
          OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
          rdfs:label "Report 14" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport15
:Report15 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :anaemia ,
                                                :cReactiveProteinIncreased ,
                                                :disseminatedIntravascularCoagulation ,
                                                :fibrinolysisIncreased ,
                                                :haematoma ,
                                                :haematuria ,
                                                :leukocytosis ,
                                                :metabolicDisorder ,
                                                :skinHaemorrhage ,
                                                :softTissueHaemorrhage ,
                                                :thrombocytopenia ,
                                                :urinaryTractInfection ,
                                                :venipunctureSiteHaemorrhage ;
          OpenPVSignal:refers_to_concomitant_drug :gabapentin ;
          OpenPVSignal:refers_to_patient :Patient15 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:time_to_onset :TimeToOnset15 ;
          OpenPVSignal:refers_to_dechallenge_outcome "negative - condition still applied" ;
          OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
          rdfs:label "Report 15" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport17
:Report17 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :acidosis ,
                                                :alkalinePhosphataseIncreased ,
                                                :altIncreased ,
                                                :astIncreased ,
                                                :atelectasis ,
                                                :bilirubinaemia ,
                                                :bronchitis ,
                                                :candidiasis ,
                                                :cardiacArrestIncident ,
                                                :cerebralDisorder ,
                                                :dermatitisExfoliative ,
                                                :ecgAbnormalSpecific ,
                                                :failureToThrive ,
                                                :fibrillationAtrial ,
                                                :gastricDilatation ,
                                                :hyperglycaemia ,
                                                :hyperuricaemia ,
                                                :infectionBacterial ,
                                                :infectionStaphylococcal ,
                                                :medicalDeviceComplication ,
                                                :neuropathyPeripheral ,
                                                :palmar-plantarErythrodysaesthesia ,
                                                :pancreatitis ,
                                                :pleuralEffusion ,
                                                :pulmonaryCongestion ,
                                                :renalFailureChronic ,
                                                :respiratoryInsufficiency ,
                                                :tachycardiaVentricular ,
                                                :thrombocytopenia ,
                                                :urinaryTractInfection ;
          OpenPVSignal:refers_to_concomitant_drug :allopurinol ,
                                                  :amlodipine ,
                                                  :clonidine ,
                                                  :colchicine ,
                                                  :daptomycin ,
                                                  :darbepoetinAlfa ,
                                                  :diphenhydramine ,
                                                  :enoxaparin ,
                                                  :famotidine ,
                                                  :insulinGlargine ,
                                                  :ipratropium ,
                                                  :lisinopril ,
                                                  :megestrol ,
                                                  :methylprednisolone ,
                                                  :omeprazole ,
                                                  :prednisolone ,
                                                  :salbutamol ,
                                                  :simvastatin ,
                                                  :sodiumBicarbonate ,
                                                  :tigecycline ,
                                                  :timolol ,
                                                  :tobramycin ,
                                                  <http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#sulfamethoxazole/trimethoprim> ;
          OpenPVSignal:refers_to_patient :Patient17 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:refers_to_secondary_suspect_drug <http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#piperacillin/tazobactam> ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 17" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport18
:Report18 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :dehydration ,
                                                :diseaseProgression ,
                                                :infection ,
                                                :thrombocytopenia ,
                                                :whiteBloodCountDecreased ;
          OpenPVSignal:refers_to_patient :Patient18 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:refers_to_outcome_after_action "death" ;
          rdfs:label "Report 18" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport2
:Report2 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :bilirubinaemia ,
                                               :rash ,
                                               :thrombocytopenia ;
         OpenPVSignal:refers_to_concomitant_drug :zolendronicAcid ;
         OpenPVSignal:refers_to_patient :Patient2 ;
         OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
         OpenPVSignal:time_to_onset :TimeToOnset2 ;
         OpenPVSignal:has_evaluation "Probable" ;
         OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
         OpenPVSignal:refers_to_outcome_after_action "recovery after drug withdrawal" ;
         OpenPVSignal:refers_to_rechallenge_outcome "negative rechallenge - condition not appeared" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport20
:Report20 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
          OpenPVSignal:refers_to_patient :Patient20 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:refers_to_secondary_suspect_drug :caffeine ,
                                                        :carvedilol ,
                                                        :natural_opium_alkaloids ,
                                                        :paracetamol ,
                                                        :spironolactone ;
          OpenPVSignal:time_to_onset :TimeToOnset20 ;
          OpenPVSignal:refers_to_dechallenge_process "false"^^xsd:boolean ;
          OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
          rdfs:label "Report 20" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport22
:Report22 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:has_free_text_reporting_element :infoForCase22 ;
          OpenPVSignal:refers_to_adverse_effect :anaemia ,
                                                :febrileNeutropenia ,
                                                :pancytopenia ,
                                                :thrombocytopenia ;
          OpenPVSignal:refers_to_concomitant_drug :atenolol ,
                                                  :calcifediol ,
                                                  :esloratadine ,
                                                  :furosemide ,
                                                  :losartan ,
                                                  :paracetamol ,
                                                  :prasozin ,
                                                  :sevelamer ,
                                                  :sodiumPolystyreneSulfonate ;
          OpenPVSignal:refers_to_patient :Patient22 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:time_to_onset :TimeToOnset22 ;
          OpenPVSignal:has_evaluation "Certain" ;
          OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
          OpenPVSignal:refers_to_outcome_after_action "recovery after drug withdrawal" ;
          OpenPVSignal:refers_to_rechallenge_outcome "positive rechallenge - condition appeared again" ;
          rdfs:label "Report 22" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport23
:Report23 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :alopecia ,
                                                :arthralgia ,
                                                :arthritis ,
                                                :arthropathy ,
                                                :arthrosis ,
                                                :fever ,
                                                :haemorrhageNos ,
                                                :hepaticEnzymesIncreased ,
                                                :hypokalaemia ,
                                                :jointSwelling ,
                                                :mass ,
                                                :pruritus ,
                                                :rash ,
                                                :rashErythematous ,
                                                :thrombocytopenia ,
                                                :urinaryTractInfection ;
          OpenPVSignal:refers_to_concomitant_drug :cyanocobalamin ,
                                                  :folicAcid ;
          OpenPVSignal:refers_to_patient :Patient23 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          OpenPVSignal:refers_to_rechallenge_outcome "negative rechallenge - condition not appeared" ;
          rdfs:label "Report 23" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport24
:Report24 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
          OpenPVSignal:refers_to_patient :Patient24 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:time_to_onset :TimeToOnset24 ;
          OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
          rdfs:label "Report 24" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport26
:Report26 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :neutropenia ,
                                                :thrombocytopenia ;
          OpenPVSignal:refers_to_concomitant_drug :fotemustine ,
                                                  :polyvalentImmunoglobulins ;
          OpenPVSignal:refers_to_patient :Patient26 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:time_to_onset :TimeToOnset26 ;
          OpenPVSignal:refers_to_dechallenge_process "false"^^xsd:boolean ;
          OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
          rdfs:label "Report 26" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport27
:Report27 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
          OpenPVSignal:refers_to_patient :Patient27 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:time_to_onset :TimeToOnset27 ;
          OpenPVSignal:refers_to_dechallenge_process "false"^^xsd:boolean ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 27" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport28
:Report28 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :bruisingOfLeg ,
                                                :purpura ,
                                                :thrombocytopenia ;
          OpenPVSignal:refers_to_patient :Patient28 ;
          OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
          OpenPVSignal:time_to_onset :TimeToOnset28 ;
          OpenPVSignal:refers_to_dechallenge_process "false"^^xsd:boolean ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 28" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport3
:Report3 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :duodenalUlcer ,
                                               :generalisedOedema ,
                                               :giHaemorrhage ,
                                               :musculoskeletalPain ,
                                               :neoplasm ,
                                               :oedema ,
                                               :pulmonaryOedema ,
                                               :thrombocytopenia ;
         OpenPVSignal:refers_to_patient :Patient3 ;
         OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
         OpenPVSignal:has_evaluation "Probable" ;
         OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
         OpenPVSignal:refers_to_outcome_after_action "recovery after drug withdrawal" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport5
:Report5 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :leukopenia ,
                                               :pancytopenia ,
                                               :paralysisFacial ,
                                               :thrombocytopenia ;
         OpenPVSignal:refers_to_patient :Patient5 ;
         OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
         OpenPVSignal:time_to_onset :TimeToOnset5 ;
         OpenPVSignal:has_evaluation "Probable" ;
         OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
         OpenPVSignal:refers_to_outcome_after_action "recovery after drug withdrawal" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport6
:Report6 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
         OpenPVSignal:refers_to_patient :Patient6 ;
         OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
         OpenPVSignal:time_to_onset :TimeToOnset6 ;
         OpenPVSignal:refers_to_dechallenge_outcome "unknown" ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport7
:Report7 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :pneumonia ,
                                               :thrombocytopenia ;
         OpenPVSignal:refers_to_patient :Patient7 ;
         OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
         OpenPVSignal:time_to_onset :TimeToOnset7 ;
         OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
         OpenPVSignal:refers_to_outcome_after_action "recovering" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport_16
:Report_16 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:VigiBase_Report ;
           OpenPVSignal:has_free_text_reporting_element :info_for_case_16 ;
           rdfs:label "Report 16" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport_25
:Report_25 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:VigiBase_Report ;
           OpenPVSignal:has_free_text_reporting_element :info_for_case_25 ;
           rdfs:label "Report 25" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport_29
:Report_29 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:VigiBase_Report ;
           OpenPVSignal:has_free_text_reporting_element :info_for_case_29 ;
           rdfs:label "Report 29" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport_30
:Report_30 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:VigiBase_Report ;
           OpenPVSignal:has_free_text_reporting_element :info_for_case_30 ;
           rdfs:label "Report 30" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport_8
:Report_8 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:has_free_text_reporting_element :info_for_case_8 ;
          rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReport_9
:Report_9 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:has_free_text_reporting_element :info_for_case_9 ;
          rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaReportsInVigibase
:ReportsInVigibase rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Free_text_reporting_element ;
                   OpenPVSignal:has_content """At the time of assessment (March 2015), there were 30 individual case safety reports (ICSRs) of thrombocytopenia in association with vemurafenib in the WHO Global ICSR database, VigiBase®. Two duplicates were identified bringing the number of assessed case reports to 28. The reports came from
10 countries: United States (9), France (8), Germany (4) and Austria, Colombia, Italy, Netherlands, Norway, Turkey and United Kingdom 1 each). Twenty-three of the ICSRs were serious and three reports were fatal.
The cases concerned 9 males and 19 females. Age was reported for 24 cases and ranged from 37 to 70 years (median age 56.5 years).
The indication for treatment was reported as malignant melanoma in 21 cases, colorectal cancer in one case and hairy cell leukaemia in one case; in the remaining five cases, the indication for treatment was reported either as unknown (three cases) or was not stated (two cases). Vemurafenib was the only suspected drug in 21 of the 28 cases: in 14 of these cases, vemurafenib was the only reported drug while the other seven cases reported concomitant medicines. In the remaining seven cases, other medicines for which thrombocytopenia is a known potential adverse effect were also suspected, including oxaliplatin, fluorouracil, cladribine, fotemustine, rituximab, aflibercept, levetiracetam, valproic acid, carvedilol, spironolactone, piperacillin/tazobactam and a combination medicine containing chlorpheniramine. Two of these ICSRs also reported co-suspected medicines that are not known to be associated with thrombocytopenia, including clobazam, folinic acid and caffeine/paracetemol/papaver somniferum latex.
The total daily dose of vemurafenib was reported in half of the cases and ranged from 240 mg to 1920 mg (median dose 1920 mg).
The time-to-onset was reported for 12 cases and ranged from 3 to 225 days, with a median time- to-onset of 20 days. Vemurafenib was withdrawn following the onset of thrombocytopenia in 12 cases: dechallenge was positive in eight of these cases, negative in one case and the outcome of dechallenge was not stated in the remaining three cases. In one case the dechallenge action was reported as dose reduced but the dechallenge outcome was not reported. In six cases the dechallenge action was reported as ‘dose not changed’: thrombocytopenia resolved in two of these cases, no effect was observed in two cases and the effect was unknown in two cases. The dechallenge action was reported as unknown in four cases, was not reported in three cases and was not applicable in two cases (due to the death of the patient). In three of the cases with a positive dechallenge, vemurafenib was subsequently reintroduced at a lower dose: one case reported recurrence of thrombocytopenia (positive rechallenge) while the remaining two cases reported no recurrence. The outcome for thrombocytopenia was reported in 19 of the cases as follows: recovered (7), recovering (4), not recovered (6) and died (2). For the remaining nine cases, the outcome was reported as unknown.
""" ;
                   rdfs:label "Reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaResponse_from_Roche
:Response_from_Roche rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Response_to_Pharmacovigilance_Signal_Report ;
                     OpenPVSignal:refers_to_pharmacovigilance_signal_report :Vemurafenib_and_thrombocytopenia ;
                     OpenPVSignal:has_content "In March 2015 the WHO Monitoring centre in Uppsala invited Roche to comment on a signal of thrombocytopenia in patients treated with vemurafenib. WHO cited 28 cases of thrombocytopenia associated with vemurafenib treatment in the VigiBase®. The report concluded that the data provided in their case series strongly supports a signal for the association between vemurafenib and thrombocytopenia. Drug induced thrombocytopenia has a reported frequency of approximately 19% to 25% in acutely ill patients. Clinical manifestation usually consists of moderate to severe thrombocytopenia (platelet count of less than 50 × 109 /L) and spontaneous bleeding which could be potentially life threatening. (Visentin & Liu, 2007) Typically, the thrombocytopenia occurs 1 to 2 weeks after the introduction of a new drug or 2-3 days after a single dose when a drug has previously been taken intermittently. Demonstration of drug-dependent anti-platelet antibodies is important to confirm the etiology of drug-induced thrombocytopenia. Recovery from drug-induced thrombocytopenia usually begins within 1 to 2 days of stopping the drug and is typically completed within a week. Drug-dependent antibodies can persist for many years. Several mechanisms have been described in the pathogenesis of drug-induced thrombocytopenia, with accelerated platelet destruction in the presence of the offending drug as the most common immune mechanism. Non immune platelet destruction associated with a small number of antineoplastic agents, such as bleomycin, can occur in thrombotic microangiopathy and its variant form, hemolytic uremic syndrome. (Goerge & Aster, 2009) The literature describes case reports of thrombocytopenia in metastatic melanoma patients as part of massive bone marrow infiltration (Deepali, Daga, & et Al, 2007), secondary to chemotherapy or immunotherapy (e.g., ipilimumab, high dose IL2), and secondary to platelet consumption in disseminated intravascular coagulation (Lepelley-Dupont, Chevrant-Breton J, & et Al, 2009). We performed an analysis on the background incidence rate of secondary thrombocytopenia and all thrombocytopenia in patients with metastatic melanoma using the Truven Healthcare MarketScan® Commercial Claims and Encounters (Commercial) database. The incidence of thrombocytopenia following a diagnosis of metastatic melanoma was estimated as 5.93 (secondary thrombocytopenia) and 42.2 (all thrombocytopenia) per 1,000 patient years. Vemurafenib inhibits mutant BRAFV600 and is approved for the treatment of adult patients with metastatic melanoma harboring this mutation. Currently the vemurafenib label does not include thrombocytopenia as an adverse drug reaction. Preclinical studies do not support a direct association with thrombocytopenia, however one case of bone marrow necrosis was noted in one of two moribund sacrificed dogs in the prematurely terminated 39-week dog study (Roche, 2015). In the Phase III trial, <1 % of 337 patients dosed with vemurafenib reported thrombocytopenia. As of March 24, 2015, there are 45 cases of thrombocytopenia related adverse events (AEs) reported with vemurafenib use in the Roche safety database, thirty-two of which were assessed as serious. Median age was 59.5 years (31-80). Gender was provided for 43 cases of which 22 were males and 21 were females. Indication was provided for 33 cases of which 32 were malignant melanoma cases and one case was hairy cell leukemia. Latency was provided for 20 of the 45 cases. Median latency was 24 days with a range of 3-225 days. Thirteen of these 20 cases had a latency of ≤ 30 days. Based on medical review, 6 out of the 45 cases were assessed to have a likely causal association to vemurafenib. The remaining cases were: a. lacking vital information that makes meaningful assessment difficult (n=20), b. have an unlikely causal association based on strong alternative etiology for the event of thrombocytopenia such as concomitant use of fotemustine, bone marrow infiltration by melanoma cells, or secondary to microangiopathy or DIC (n=13); and c. assessed to have possible causal association based on the latency that was longer than expected for drug-induced thrombocytopenia or a negative dechallenge/ rechallenge (n=6). Table 1 below provides the case details on the 6 cases that are assessed to have a likely causal association based on case presentation, temporal association, and dechallenge information. Of the 6 cases, two cases had associated depression of other blood cell lineage. AER number 1351266 was identified in the WHO Report as case 22 and where causal relationship between vemurafenib and thrombocytopenia was described as “certain” in that report. Similarly, Roche assessed this case to be likely associated with vemurafenib treatment. The 6 cases of thrombocytopenia yield a crude reporting rate of 0.67 cases per 1000 patient years based on an estimated cumulative patient exposure to vemurafenib of 17,729 patient years. Using a conservative approach, the crude reporting rate of 45 cases is 2.54 per 1,000 patient years. These rates are significantly lower than expected for the metastatic melanoma population based on the Marketscan analysis. Roche acknowledges the signal for thrombocytopenia raised by the WHO. This event including other cell lines and pancytopenia are closely monitored. Bone marrow toxicity remains a potential risk for vemurafenib and is included in the Risk Management Plan (RMP) for the drug. The assessment of this event, as part of bicytopenia or pancytopenia in the context of bone marrow suppression is currently being investigated by Roche. References 1. Bluteau, D., Raslova, H., & et Al. (2014). Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. The Journal of Clinical Investigations, 124(2), 580-91. 2. Clerico, M., et Al, & Turrisi G. (2006). Persistent thrombocytopenia during melanoma treatment with fotemustine. Melanoma Research, 16(6), 543-4. 3. Deepali, J., Daga, M., & et Al. (2007). Metastatic Malignant Mellanoma in Bone Marrow with Occult Primary Site - a Case Report with Review of Literature. Diagnostic Pathology, 2(38). 4. Goerge, J., & Aster, R. (2009). Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. ASH education book, 1, 153-8. 5. Lepelley-Dupont, C., Chevrant-Breton J, & et Al. (2009). Melanoma-associated disseminated intravascular coagulation. Journal of the European Academoy of Dermatology and Venerology, 23(6), 720-1. 6. Roche, F. H.-L. (2015). Investigator’s Brochure for vemurafenib. 7. Visentin, G., & Liu, C. (2007). Drug induced thrombocytopenia. Hematology Oncology clinics of Norht America, 21(4), 685-96." ;
                     rdfs:label "Response from Roche" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaSummaryContent
:SummaryContent rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Summary ;
                OpenPVSignal:has_content "Vemurafenib is a protein kinase inhibitor with activity against mutated B-RAF protein; it is used in the treatment of metastatic or unresectable malignant melanoma that carries the BRAF V600E mutation. B-RAF protein acts in the RAS-RAF-MEK- ERK intracellular signalling pathway that leads to cell growth and proliferation: by targeting mutated B-RAF, vemurafenib inhibits the growth of melanoma cells containing the mutated B-RAF gene. At the time of assessment (March 2015), The WHO Global Individual Case Safety Report (ICSR) database, VigiBase® contains 28 ICSRs in which vemurafenib is associated with thrombocytopenia (after exclusion of two duplicates). One case provides information that suggests a ‘certain’ causal relationship between vemurafenib and thrombocytopenia, four cases suggest a ‘probable’ causal relationship and a further 14 cases can be assessed to have a ‘possible’ causal relationship to vemurafenib. Six cases include co-reported ADR terms that indicate a more widespread myelosuppression, rather than an isolated thrombocytopenia. The RAS-RAF-MEK- ERK intracellular signalling pathway is involved in the production and differentiation of haematopoietic progenitor cells. It is possible that thrombocytopenia associated with vemurafenib may be part of a spectrum of drug induced myelosuppression, possibly brought about through an effect on the RAS-RAF-MEK-ERK intracellular signalling pathway in haematopoietic progenitor cells." ;
                rdfs:label "Summary content" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaThrombocytopenia
:Thrombocytopenia rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Free_text_reporting_element ;
                  OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
                  OpenPVSignal:has_content "Thrombocytopenia is defined as a platelet count of less than 150 x 109/L (150 000 per μL). A grading system for thrombocytopenia has been developed by the United States National Cancer Institute in which platelet counts between 75 x 109/L and 150 x 109/L are classified as Grade 1, while platelet counts below 25 x 109/L are classified as Grade 4.4 Patients with platelet counts above 20 x 109/L are usually asymptomatic, but the risk of spontaneous mucocutaneous bleeding (gingival bleed, epistaxis, menorrhagia, petechiae and ecchymoses) and life- threatening, spontaneous intracranial hemorrhage or gastrointestinal bleeding increases rapidly with platelet counts below 10 x 109/L." ;
                  rdfs:label "Thrombocytopenia pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset11
:TimeToOnset11 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericPosition 43 ;
               rdfs:label "Time to onset 11" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset12
:TimeToOnset12 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericPosition 4 ;
               rdfs:label "Time to onset 12" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset13
:TimeToOnset13 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericPosition 15 ;
               rdfs:label "Time to onset 13" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset14
:TimeToOnset14 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericPosition 7 ;
               rdfs:label "Time to onset 14" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset15
:TimeToOnset15 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericPosition 3 ;
               rdfs:label "Time to onset 15" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset2
:TimeToOnset2 rdf:type owl:NamedIndividual ,
                       time:DurationDescription ;
              time:nominalPosition "days" ;
              time:numericPosition 20 ;
              rdfs:label "Time to onset 2" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset20
:TimeToOnset20 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericPosition 163 ;
               rdfs:label "Time to onset 20" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset22
:TimeToOnset22 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericPosition 19 ;
               rdfs:label "Time to onset 22" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset24
:TimeToOnset24 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericPosition 169 ;
               rdfs:label "Time to onset 24" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset26
:TimeToOnset26 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericPosition 79 ;
               rdfs:label "Time to onset 26" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset27
:TimeToOnset27 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               time:nominalPosition "days" ;
               time:numericPosition 55 ;
               rdfs:label "Time to onset 27" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset28
:TimeToOnset28 rdf:type owl:NamedIndividual ,
                        time:DurationDescription ;
               OpenPVSignal:has_content "more than 122 " ;
               rdfs:label "Time to onset 28" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset5
:TimeToOnset5 rdf:type owl:NamedIndividual ,
                       time:DurationDescription ;
              time:nominalPosition "days" ;
              time:numericPosition 29 ;
              rdfs:label "Time to onset 5" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset6
:TimeToOnset6 rdf:type owl:NamedIndividual ,
                       time:DurationDescription ;
              OpenPVSignal:has_content "less than 7 " ;
              rdfs:label "Time to onset 6" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaTimeToOnset7
:TimeToOnset7 rdf:type owl:NamedIndividual ,
                       time:DurationDescription ;
              time:nominalPosition "days" ;
              time:numericPosition 46 ;
              rdfs:label "Time to onset 7" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaVemurafenib_and_granulocytopenia
:Vemurafenib_and_granulocytopenia rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Warning_Information ;
                                  OpenPVSignal:refers_to_adverse_effect :granulocytopenia ,
                                                                        :neutropenia ;
                                  OpenPVSignal:refers_to_drug :vemurafenib ;
                                  mp:citation "Granulocytopenia has previously been signalled for vemurafenib (SIGNAL, issue 3, 2013) and neutropenia has since been added to the US, UK and EMA product information sheets, adding support to the notion that vemurafenib may affect the RAS-RAF-MEK- ERK cascade in haematopoietic cells." ;
                                  rdfs:label "Vemurafenib and granulocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaVemurafenib_and_thrombocytopenia
:Vemurafenib_and_thrombocytopenia rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Pharmacovigilance_Signal_Report ;
                                  OpenPVSignal:refers_to_author :Dr_Geraldine_Hill ;
                                  OpenPVSignal:refers_to_signal :pvSignal ;
                                  OpenPVSignal:has_creation_date "01/06/2015" ;
                                  OpenPVSignal:has_overall_conclusion "causal association" ;
                                  rdfs:label "Vemurafenib and thrombocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaacidosis
:acidosis rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10000486 ;
          OpenPVSignal:has_MedDRA_prefered_term "Acidosis" ;
          rdfs:label "acidosis" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaaflibercept
:aflibercept rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "S01LA05" ;
             rdfs:label "aflibercept" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaalkalinePhosphataseIncreased
:alkalinePhosphataseIncreased rdf:type owl:NamedIndividual ,
                                       OpenPVSignal:Adverse_Effect ;
                              OpenPVSignal:has_MedDRA_code 10059570 ;
                              OpenPVSignal:has_MedDRA_prefered_term "Blood alkaline phosphatase increased" ;
                              rdfs:label "alkaline phosphatase increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaallopurinol
:allopurinol rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "M04AA01" ;
             rdfs:label "allopurinol" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaalopecia
:alopecia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10001760 ;
          OpenPVSignal:has_MedDRA_prefered_term "Alopecia" ;
          rdfs:label "alopecia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaaltIncreased
:altIncreased rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10001551 ;
              OpenPVSignal:has_MedDRA_prefered_term "Alanine aminotransferase increased" ;
              rdfs:label "alt increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaamlodipine
:amlodipine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C08CA01" ;
            rdfs:label "amlodipine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaanaemia
:anaemia rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10002034 ;
         OpenPVSignal:has_MedDRA_prefered_term "Anaemia" ;
         rdfs:label "anaemia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaarthralgia
:arthralgia rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10003239 ;
            OpenPVSignal:has_MedDRA_prefered_term "Arthralgia" ;
            rdfs:label "arthralgia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaarthritis
:arthritis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10003246 ;
           OpenPVSignal:has_MedDRA_prefered_term "Arthritis" ;
           rdfs:label "arthritis" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaarthropathy
:arthropathy rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10003285 ;
             OpenPVSignal:has_MedDRA_prefered_term "Arthropathy" ;
             rdfs:label "arthropathy" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaarthrosis
:arthrosis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10031161 ;
           OpenPVSignal:has_MedDRA_prefered_term "Osteoarthritis" ;
           rdfs:label "arthrosis" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaastIncreased
:astIncreased rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10003481 ;
              OpenPVSignal:has_MedDRA_prefered_term "Aspartate aminotransferase increased" ;
              rdfs:label "ast increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaatelectasis
:atelectasis rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10003598 ;
             OpenPVSignal:has_MedDRA_prefered_term "Atelectasis" ;
             rdfs:label "atelectasis" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaatenolol
:atenolol rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "C07AB03" ;
          rdfs:label "atenolol" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniabilirubinaemia
:bilirubinaemia rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10020578 ;
                OpenPVSignal:has_MedDRA_prefered_term "Hyperbilirubinaemia" ;
                rdfs:label "bilirubinaemia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniablackEyeHaemorrhage
:blackEyeHaemorrhage rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10004972 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Black eye" ;
                     rdfs:label "black eye" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniabrafv600eMutationPositive
:brafv600eMutationPositive rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Indication ;
                           OpenPVSignal:has_MedDRA_code 10075676 ;
                           OpenPVSignal:has_MedDRA_prefered_term "BRAF V600E mutation positive" ;
                           rdfs:label "braf v600e mutation positive" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniabronchitis
:bronchitis rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10006451 ;
            OpenPVSignal:has_MedDRA_prefered_term "Bronchitis" ;
            rdfs:label "bronchitis" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniabruisingOfLeg
:bruisingOfLeg rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10006510 ;
               OpenPVSignal:has_MedDRA_prefered_term "Bruising of leg" ;
               rdfs:label "bruising of leg" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacReactiveProteinIncreased
:cReactiveProteinIncreased rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Adverse_Effect ;
                           OpenPVSignal:has_MedDRA_code 10006825 ;
                           OpenPVSignal:has_MedDRA_prefered_term "C-reactive protein increased" ;
                           rdfs:label "c reactive protein increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacaffeine
:caffeine rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "N06BC01" ;
          rdfs:label "caffeine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacalcifediol
:calcifediol rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "A11CC06 " ;
             rdfs:label "calcifediol" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacandidiasis
:candidiasis rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10074170 ;
             OpenPVSignal:has_MedDRA_prefered_term "Candida infection" ;
             rdfs:label "candidiasis" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacardiacArrestIncident
:cardiacArrestIncident rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_MedDRA_code 10007515 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Cardiac arrest" ;
                       rdfs:label "cardiac arrest incident" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacarvedilol
:carvedilol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C07AG02" ;
            rdfs:label "carvedilol" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacerebralDisorder
:cerebralDisorder rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_MedDRA_code 10054938 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Cerebral disorder" ;
                  rdfs:label "cerebral disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniachlorpheniramine
:chlorpheniramine rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Drug ;
                  OpenPVSignal:has_ATC_code "R06AB04" ;
                  rdfs:label "chlorpheniramine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacladribine
:cladribine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "L04AA40" ;
            rdfs:label "cladribine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaclonidine
:clonidine rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "C02AC01" ;
           rdfs:label "clonidine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacolchicine
:colchicine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "M04AC01" ;
            rdfs:label "colchicine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacolorectal_cancer
:colorectal_cancer rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Indication ;
                   OpenPVSignal:has_MedDRA_code 10061451 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Colorectal cancer" ;
                   rdfs:label "colorectal cancer" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniacyanocobalamin
:cyanocobalamin rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "B03BA0" ;
                rdfs:label "cyanocobalamin" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniadaptomycin
:daptomycin rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "J01XX09" ;
            rdfs:label "daptomycin" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniadarbepoetinAlfa
:darbepoetinAlfa rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Drug ;
                 OpenPVSignal:has_ATC_code "B03XA02" ;
                 rdfs:label "darbepoetin alfa" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniadehydration
:dehydration rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10012174 ;
             OpenPVSignal:has_MedDRA_prefered_term "Dehydration" ;
             rdfs:label "dehydration" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniadermatitisExfoliative
:dermatitisExfoliative rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_MedDRA_code 10012455 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Dermatitis exfoliative" ;
                       rdfs:label "dermatitis exfoliative" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniadiphenhydramine
:diphenhydramine rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Drug ;
                 OpenPVSignal:has_ATC_code "D04AA32 " ;
                 rdfs:label "diphenhydramine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniadiseaseProgression
:diseaseProgression rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10061818 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Disease progression" ;
                    rdfs:label "disease progression" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniadisseminatedIntravascularCoagulation
:disseminatedIntravascularCoagulation rdf:type owl:NamedIndividual ,
                                               OpenPVSignal:Adverse_Effect ;
                                      OpenPVSignal:has_MedDRA_code 10013442 ;
                                      OpenPVSignal:has_MedDRA_prefered_term "Disseminated intravascular coagulation" ;
                                      rdfs:label "disseminated intravascular coagulation" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaduodenalUlcer
:duodenalUlcer rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10013836 ;
               OpenPVSignal:has_MedDRA_prefered_term "Duodenal ulcer" ;
               rdfs:label "duodenal ulcer" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaecchymoses
:ecchymoses rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10014080 ;
            OpenPVSignal:has_MedDRA_prefered_term "Ecchymosis" ;
            rdfs:label "ecchymoses" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaecgAbnormalSpecific
:ecgAbnormalSpecific rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10014088 ;
                     OpenPVSignal:has_MedDRA_prefered_term "ECG abnormal specific" ;
                     rdfs:label "ecg abnormal specific" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaenoxaparin
:enoxaparin rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "B01AB05" ;
            rdfs:label "enoxaparin" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaepistaxis
:epistaxis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10015090 ;
           OpenPVSignal:has_MedDRA_prefered_term "Epistaxis" ;
           rdfs:label "epistaxis" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaesloratadine
:esloratadine rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "R06AX27" ;
              rdfs:label "esloratadine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniafailureToThrive
:failureToThrive rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_MedDRA_code 10016165 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Failure to thrive" ;
                 rdfs:label "failure to thrive" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniafamotidine
:famotidine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A02BA03 " ;
            rdfs:label "famotidine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniafebrileNeutropenia
:febrileNeutropenia rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10016288 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Febrile neutropenia" ;
                    rdfs:label "febrile neutropenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniafever
:fever rdf:type owl:NamedIndividual ,
                OpenPVSignal:Adverse_Effect ;
       OpenPVSignal:has_MedDRA_code 10037660 ;
       OpenPVSignal:has_MedDRA_prefered_term "Pyrexia" ;
       rdfs:label "fever" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniafibrillationAtrial
:fibrillationAtrial rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10003658 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Atrial fibrillation" ;
                    rdfs:label "fibrillation atrial" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniafibrinolysisIncreased
:fibrinolysisIncreased rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_MedDRA_code 10016607 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Fibrinolysis increased" ;
                       rdfs:label "fibrinolysis increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniafluorouracil
:fluorouracil rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "L01BC02" ;
              rdfs:label "fluorouracil" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniafolicAcid
:folicAcid rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "B03BB01 " ;
           rdfs:label "folic acid" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniafotemustine
:fotemustine rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "L01AD05" ;
             rdfs:label "fotemustine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniafurosemide
:furosemide rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C03CA01" ;
            rdfs:label "furosemide" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniagabapentin
:gabapentin rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N03AX12" ;
            rdfs:label "gabapentin" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniagastricDilatation
:gastricDilatation rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_MedDRA_code 10017779 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Gastric dilatation" ;
                   rdfs:label "gastric dilatation" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniagastrointestinalBleeding
:gastrointestinalBleeding rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_MedDRA_code 10017955 ;
                          OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal haemorrhage" ;
                          rdfs:label "gastrointestinal bleeding" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniageneralisedOedema
:generalisedOedema rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_MedDRA_code 10018092 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Generalised oedema" ;
                   rdfs:label "generalised oedema" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniagiHaemorrhage
:giHaemorrhage rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10017955 ;
               OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal haemorrhage" ;
               rdfs:label "gi haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniagingivalBleed
:gingivalBleed rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10018276 ;
               OpenPVSignal:has_MedDRA_prefered_term "Gingival bleeding" ;
               rdfs:label "gingival bleed" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniagranulocytopenia
:granulocytopenia rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_MedDRA_code 10018687 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Granulocytopenia" ;
                  rdfs:label "granulocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniahaematoma
:haematoma rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10018852 ;
           OpenPVSignal:has_MedDRA_prefered_term "Haematoma" ;
           rdfs:label "haematoma" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniahaematuria
:haematuria rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10018867 ;
            OpenPVSignal:has_MedDRA_prefered_term "Haematuria" ;
            rdfs:label "haematuria" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniahaemorrhageNos
:haemorrhageNos rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10055798 ;
                OpenPVSignal:has_MedDRA_prefered_term "Haemorrhage" ;
                rdfs:label "haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniahairyCellLeukemia
:hairyCellLeukemia rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ,
                            OpenPVSignal:Indication ;
                   OpenPVSignal:has_MedDRA_code 10019053 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Hairy cell leukaemia" ;
                   rdfs:label "hairy cell leukemia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniahepaticEnzymesIncreased
:hepaticEnzymesIncreased rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_MedDRA_code 10060795 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Hepatic enzyme increased" ;
                         rdfs:label "hepatic enzymes increased" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniahyperglycaemia
:hyperglycaemia rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10020635 ;
                OpenPVSignal:has_MedDRA_prefered_term "Hyperglycaemia" ;
                rdfs:label "hyperglycaemia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniahyperuricaemia
:hyperuricaemia rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10020903 ;
                OpenPVSignal:has_MedDRA_prefered_term "Hyperuricaemia" ;
                rdfs:label "hyperuricaemia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniahypokalaemia
:hypokalaemia rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10021015 ;
              OpenPVSignal:has_MedDRA_prefered_term "Hypokalaemia" ;
              rdfs:label "hypokalaemia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainfection
:infection rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10021789 ;
           OpenPVSignal:has_MedDRA_prefered_term "Infection" ;
           rdfs:label "infection" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainfectionBacterial
:infectionBacterial rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10060945 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Bacterial infection" ;
                    rdfs:label "infection bacterial" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainfectionStaphylococcal
:infectionStaphylococcal rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_MedDRA_code 10058080 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Staphylococcal infection" ;
                         rdfs:label "infection staphylococcal" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainfoForCase22
:infoForCase22 rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Case_Report_Information ;
               OpenPVSignal:has_content """Case 22 provides the strongest evidence in this series for a causal relationship between vemurafenib and thrombocytopenia in that it has a plausible time relationship to drug exposure, no alternative explanation for the ADR, a positive dechallenge and a positive rechallenge. The case concerns a 65 year old female with a history of end-stage renal disease, arterial hypertension and a previous DVT. Thrombocytopenia and anaemia developed 19 days after initiation of treatment with vemurafenib for melanoma, and pancytopenia with febrile neutropenia developed on day 22 of therapy. Platelets were transfused. Vemurafenib was stopped for six days, during which time the platelet count improved; vemurafenib was then reintroduced at half the original dose but three days later the platelet count had again dropped, consistent with a positive rechallenge.
Vemurafenib was stopped definitively and the platelet count returned to normal. Clinical investigations ruled out alternative explanations for the thrombocytopenia.""" ;
               rdfs:label "info for case 22" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainfo_for_case_16
:info_for_case_16 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Case_Report_Information ;
                  OpenPVSignal:has_content "in Cases 9 and 16, the thrombocytopenia appears to have preceded treatment with vemurafenib" ;
                  rdfs:label "info for case 16" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainfo_for_case_25
:info_for_case_25 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Case_Report_Information ;
                  OpenPVSignal:has_content "in Cases 25, 29 and 30, the temporal relationship to other medicines provides a more plausible alternative explanation for the thrombocytopenia." ;
                  rdfs:label "info for case 25" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainfo_for_case_29
:info_for_case_29 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Case_Report_Information ;
                  OpenPVSignal:has_content "in Cases 25, 29 and 30, the temporal relationship to other medicines provides a more plausible alternative explanation for the thrombocytopenia." ;
                  rdfs:label "info for case 29" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainfo_for_case_30
:info_for_case_30 rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Case_Report_Information ;
                  OpenPVSignal:has_content "in Cases 25, 29 and 30, the temporal relationship to other medicines provides a more plausible alternative explanation for the thrombocytopenia." ;
                  rdfs:label "info for case 30" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainfo_for_case_8
:info_for_case_8 rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Case_Report_Information ;
                 OpenPVSignal:has_content "In Case 8, the patient received radiation therapy to the lumbar vertebrae one day prior to starting treatment with vemurafenib and the thrombocytopenia improved while treatment with vemurafenib continued;" ;
                 rdfs:label "info for case 8" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainfo_for_case_9
:info_for_case_9 rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Case_Report_Information ;
                 OpenPVSignal:has_content "in Cases 9 and 16, the thrombocytopenia appears to have preceded treatment with vemurafenib" ;
                 rdfs:label "info for case 9" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniainsulinGlargine
:insulinGlargine rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Drug ;
                 OpenPVSignal:has_ATC_code "A10AE04" ;
                 rdfs:label "insulin glargine" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaintracranialHemorrhage
:intracranialHemorrhage rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_MedDRA_code 10018985 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Haemorrhage intracranial" ;
                        rdfs:label "intracranial hemorrhage " .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaipratropium
:ipratropium rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "R03BB01" ;
             rdfs:label "ipratropium" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniajointSwelling
:jointSwelling rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_MedDRA_code 10023232 ;
               OpenPVSignal:has_MedDRA_prefered_term "Joint swelling" ;
               rdfs:label "joint swelling" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenialeukocytosis
:leukocytosis rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10024378 ;
              OpenPVSignal:has_MedDRA_prefered_term "Leukocytosis" ;
              rdfs:label "leukocytosis" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenialeukopenia
:leukopenia rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10024384 ;
            OpenPVSignal:has_MedDRA_prefered_term "Leukopenia" ;
            rdfs:label "leukopenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenialevetiracetam
:levetiracetam rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "N03AX14" ;
               rdfs:label "levetiracetam" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenialevetiracetam_and_thrombocytopenia
:levetiracetam_and_thrombocytopenia rdf:type owl:NamedIndividual ,
                                             obo:OAE_0001182 ;
                                    OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
                                    OpenPVSignal:refers_to_drug :levetiracetam ;
                                    OpenPVSignal:has_content "Levetiracteam, which is known to be associated with thrombocytopenia, was listed as a concomitant medicine in Case 11." ;
                                    rdfs:label "levetiracetam and thrombocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenialisinopril
:lisinopril rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C09AA03" ;
            rdfs:label "lisinopril" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenialosartan
:losartan rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "C09CA01" ;
          rdfs:label "losartan" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniamass
:mass rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_MedDRA_code 10026865 ;
      OpenPVSignal:has_MedDRA_prefered_term "Mass" ;
      rdfs:label "mass" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniamedianDosage
:medianDosage rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Dosage ;
              OpenPVSignal:refers_to_drug :vemurafenib ;
              OpenPVSignal:has_content "The total daily dose of vemurafenib was reported in half of the cases and ranged from 240 mg to 1920 mg (median dose 1920 mg)." ;
              OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
              OpenPVSignal:has_value 1920 ;
              OpenPVSignal:refers_to_dose_value "1920 mg" ;
              rdfs:label "dosage info" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniamedianTimeToOnset
:medianTimeToOnset rdf:type owl:NamedIndividual ,
                            time:DurationDescription ;
                   OpenPVSignal:has_content "The time-to-onset was reported for 12 cases and ranged from 3 to 225 days, with a median time- to-onset of 20 days." ;
                   time:nominalPosition "days" ;
                   time:numericPosition 20 ;
                   rdfs:label "time to onset info" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniamedicalDeviceComplication
:medicalDeviceComplication rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Adverse_Effect ;
                           OpenPVSignal:has_MedDRA_code 10077107 ;
                           OpenPVSignal:has_MedDRA_prefered_term "Complication associated with device" ;
                           rdfs:label "medical device complication" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniamegestrol
:megestrol rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "G03AC05" ;
           rdfs:label "megestrol" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniamelanoma
:melanoma rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ,
                   OpenPVSignal:Indication ;
          OpenPVSignal:has_MedDRA_code 10025650 ;
          OpenPVSignal:has_MedDRA_prefered_term "Malignant melanoma" ;
          rdfs:label "malignant melanoma" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniamenorrhagia
:menorrhagia rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10027313 ;
             OpenPVSignal:has_MedDRA_prefered_term "Menorrhagia" ;
             rdfs:label "menorrhagia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniametabolicDisorder
:metabolicDisorder rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_MedDRA_code 10058097 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Metabolic disorder" ;
                   rdfs:label "metabolic disorder" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniamethylprednisolone
:methylprednisolone rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug ;
                    OpenPVSignal:has_ATC_code "D07AA01" ;
                    rdfs:label "methylprednisolone" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniamusculoskeletalPain
:musculoskeletalPain rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10028391 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Musculoskeletal pain" ;
                     rdfs:label "musculoskeletal pain" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenianatural_opium_alkaloids
:natural_opium_alkaloids rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Drug ;
                         OpenPVSignal:has_content "papaver somniferum latex" ;
                         OpenPVSignal:has_ATC_code "N02AA" ;
                         rdfs:label "Natural Opium Alkaloids" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenianeoplasm
:neoplasm rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10028980 ;
          OpenPVSignal:has_MedDRA_prefered_term "Neoplasm" ;
          rdfs:label "neoplasm" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenianeuropathyPeripheral
:neuropathyPeripheral rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_MedDRA_code 10029331 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Neuropathy peripheral" ;
                      rdfs:label "neuropathy peripheral" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenianeutropenia
:neutropenia rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10029354 ;
             OpenPVSignal:has_MedDRA_prefered_term "Neutropenia" ;
             rdfs:label "neutropenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaoedema
:oedema rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_MedDRA_code 10030095 ;
        OpenPVSignal:has_MedDRA_prefered_term "Oedema" ;
        rdfs:label "oedema" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaomeprazole
:omeprazole rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A02BC01" ;
            rdfs:label "omeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaother_medicines_with_thrombocytopenia
:other_medicines_with_thrombocytopenia rdf:type owl:NamedIndividual ,
                                                obo:OAE_0001182 ,
                                                OpenPVSignal:Warning_Information ;
                                       OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
                                       OpenPVSignal:refers_to_drug :aflibercept ,
                                                                   :carvedilol ,
                                                                   :chlorpheniramine ,
                                                                   :cladribine ,
                                                                   :fluorouracil ,
                                                                   :fotemustine ,
                                                                   :levetiracetam ,
                                                                   :oxaliplation ,
                                                                   :rituximab ,
                                                                   :spironolactone ,
                                                                   :valproic_acid ,
                                                                   <http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#piperacillin/tazobactam> ;
                                       OpenPVSignal:has_content "In the remaining seven cases, other medicines for which thrombocytopenia is a known potential adverse effect were also suspected, including oxaliplatin, fluorouracil, cladribine, fotemustine, rituximab, aflibercept, levetiracetam, valproic acid, carvedilol, spironolactone, piperacillin/tazobactam and a combination medicine containing chlorpheniramine." ;
                                       rdfs:label "other medicines with thrombocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaoverallReportsInVigibase
:overallReportsInVigibase rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Reports_group ;
                          OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
                          OpenPVSignal:refers_to_drug :vemurafenib ;
                          OpenPVSignal:has_count 28 ;
                          OpenPVSignal:has_count_of_men 9 ;
                          OpenPVSignal:has_count_of_women 19 ;
                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                          rdfs:label "overall reports in vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaoxaliplation
:oxaliplation rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "L01XA03" ;
              rdfs:label "oxaliplatin" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapalmar-plantarErythrodysaesthesia
:palmar-plantarErythrodysaesthesia rdf:type owl:NamedIndividual ,
                                            OpenPVSignal:Adverse_Effect ;
                                   OpenPVSignal:has_MedDRA_code 10033553 ;
                                   OpenPVSignal:has_MedDRA_prefered_term "Palmar-plantar erythrodysaesthesia syndrome" ;
                                   rdfs:label "palmar-plantar erythrodysaesthesia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapancreatitis
:pancreatitis rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10033645 ;
              OpenPVSignal:has_MedDRA_prefered_term "Pancreatitis" ;
              rdfs:label "pancreatitis" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapancytopenia
:pancytopenia rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10033661 ;
              OpenPVSignal:has_MedDRA_prefered_term "Pancytopenia" ;
              rdfs:label "pancytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaparacetamol
:paracetamol rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N02BE01" ;
             rdfs:label "Paracetamol" ,
                        "paracetamol" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaparalysisFacial
:paralysisFacial rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_MedDRA_code 10016062 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Facial paralysis" ;
                 rdfs:label "paralysis facial" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapetechiae
:petechiae rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10034754 ;
           OpenPVSignal:has_MedDRA_prefered_term "Petechiae" ;
           rdfs:label "petechiae" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapleuralEffusion
:pleuralEffusion rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_MedDRA_code 10035598 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Pleural effusion" ;
                 rdfs:label "pleural effusion" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapneumonia
:pneumonia rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10035664 ;
           OpenPVSignal:has_MedDRA_prefered_term "Pneumonia" ;
           rdfs:label "pneumonia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapolyvalentImmunoglobulins
:polyvalentImmunoglobulins rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Drug ;
                           OpenPVSignal:has_ATC_code "J06BA" ;
                           rdfs:label "polyvalent immunoglobulins" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaprasozin
:prasozin rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "02CA01 " ;
          rdfs:label "prasozin" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaprednisolone
:prednisolone rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A07EA01" ;
              rdfs:label "prednisolone" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaproduct_labelling
:product_labelling rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Structured_Product_Labels_information ,
                            OpenPVSignal:Warning_Information ;
                   OpenPVSignal:refers_to_adverse_effect :neutropenia ;
                   OpenPVSignal:refers_to_drug :vemurafenib ;
                   mp:references :Ref.3 ,
                                 :Ref.6 ,
                                 :Ref.7 ;
                   OpenPVSignal:has_content "Thrombocytopenia is not listed as a possible ADR for vemurafenib in any of the sources that were checked, including the EMA6, UK Summary of Product Characteristics7 and the US FDA Product Label.3 Neutropenia is the only haematological ADR listed in the product information." ;
                   rdfs:label "product labelling" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapruritus
:pruritus rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10037087 ;
          OpenPVSignal:has_MedDRA_prefered_term "Pruritus" ;
          rdfs:label "pruritus" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapulmonaryCongestion
:pulmonaryCongestion rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10037368 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Pulmonary congestion" ;
                     rdfs:label "pulmonary congestion" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapulmonaryOedema
:pulmonaryOedema rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_MedDRA_code 10037423 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Pulmonary oedema" ;
                 rdfs:label "pulmonary oedema" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapurpura
:purpura rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10037549 ;
         OpenPVSignal:has_MedDRA_prefered_term "Purpura" ;
         rdfs:label "purpura" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniapvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Signal ;
          OpenPVSignal:Free_text_reporting_element :ConclusionContent ,
                                                   :DiscussionContent ,
                                                   :IntroductionContent ,
                                                   :ReportsInVigibase ,
                                                   :SummaryContent ,
                                                   :Thrombocytopenia ;
          OpenPVSignal:is_supported_by_individual_case_report :Report11 ,
                                                              :Report12 ,
                                                              :Report13 ,
                                                              :Report14 ,
                                                              :Report15 ,
                                                              :Report17 ,
                                                              :Report18 ,
                                                              :Report2 ,
                                                              :Report20 ,
                                                              :Report22 ,
                                                              :Report23 ,
                                                              :Report24 ,
                                                              :Report26 ,
                                                              :Report27 ,
                                                              :Report28 ,
                                                              :Report3 ,
                                                              :Report5 ,
                                                              :Report6 ,
                                                              :Report7 ,
                                                              :Report_16 ,
                                                              :Report_25 ,
                                                              :Report_29 ,
                                                              :Report_30 ,
                                                              :Report_8 ,
                                                              :Report_9 ;
          OpenPVSignal:is_supported_by_statistical_entity :overallReportsInVigibase ,
                                                          :reportsFromAustria ,
                                                          :reportsFromColombia ,
                                                          :reportsFromFrance ,
                                                          :reportsFromGermany ,
                                                          :reportsFromItaly ,
                                                          :reportsFromNetherlands ,
                                                          :reportsFromNorway ,
                                                          :reportsFromTurkey ,
                                                          :reportsFromUnitedKingdom ,
                                                          :reportsFromUnitedStates ,
                                                          :reportsWithDechallengeStatusDoseNotChanged ,
                                                          :reportsWithDechallengeStatusDoseNotchanged_ThrombocytopeniaPersisting ,
                                                          :reportsWithDechallengeStatusDoseNotchanged_ThrombocytopeniaResolving ,
                                                          :reportsWithFatalOutcome ,
                                                          :reportsWithNegativeDechallenge ,
                                                          :reportsWithNotRecovered ,
                                                          :reportsWithPositiveDechallenge ,
                                                          :reportsWithRecoveredAsOutcome ,
                                                          :reportsWithRecoveringAsOutcome ,
                                                          :reportsWithSeriousOutcome ,
                                                          :reportsWithUnknownOutcome ,
                                                          :reportsWithUnknownOutcomeInDechallenge ,
                                                          :reportsWithVemurafenibAsTheOnlySuspectDrug ,
                                                          :reportsWithVemurafenibTheOnlyDrug ,
                                                          :reports_with_age_info ,
                                                          :reports_with_colorectal_cancer_as_indication ,
                                                          :reports_with_dose_info ,
                                                          :reports_with_evaluation_certain ,
                                                          :reports_with_evaluation_possible ,
                                                          :reports_with_evaluation_probable ,
                                                          :reports_with_hairy_cell_leukaemia_as_indication ,
                                                          :reports_with_malignant_melanoma_as_indication ,
                                                          :reports_with_negative_rechallenge ,
                                                          :reports_with_partial_dechallenge ,
                                                          :reports_with_positive_rechallenge ,
                                                          :reports_with_time_to_onset_info ;
          OpenPVSignal:refers_to_adverse_effect :thrombocytopenia ;
          OpenPVSignal:refers_to_drug :vemurafenib ;
          OpenPVSignal:refers_to_primary_suspect_drug :Thrombocytopenia ;
          mp:supportedByData :IndicationAsAConfounder ,
                             :Vemurafenib_and_granulocytopenia ,
                             :levetiracetam_and_thrombocytopenia ,
                             :other_medicines_with_thrombocytopenia ,
                             :product_labelling ,
                             :reportsLackingCausality ;
          OpenPVSignal:initially_identified_on "01/06/2015" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniarash
:rash rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_MedDRA_code 10037844 ;
      OpenPVSignal:has_MedDRA_prefered_term "Rash" ;
      rdfs:label "rash" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniarashErythematous
:rashErythematous rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_MedDRA_code 10037855 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Rash erythematous" ;
                  rdfs:label "rash erythematous" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniarecommendedDoseForVemurafenib
:recommendedDoseForVemurafenib rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Dosage ;
                               OpenPVSignal:refers_to_drug :vemurafenib ;
                               OpenPVSignal:refers_to_interval_between_administrations <http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#12HoursIntervalBetweenAdministrations> ;
                               mp:references :Ref.3 ;
                               OpenPVSignal:has_content "The recommended dose is 960 mg twice daily and it is currently available in 240 mg tablets" ;
                               OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
                               OpenPVSignal:has_value 960 ;
                               OpenPVSignal:refers_to_dose_value "960 mg" ;
                               rdfs:label "recommended dose for vemurafenib" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniarenalFailureChronic
:renalFailureChronic rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10064848 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Chronic kidney disease" ;
                     rdfs:label "renal failure chronic" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsFromAustria
:reportsFromAustria rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Reports_group ;
                    OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                    OpenPVSignal:has_count 1 ;
                    OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Austria" ;
                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                    rdfs:label "reports from Austria" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsFromColombia
:reportsFromColombia rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Reports_group ;
                     OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                     OpenPVSignal:has_count 1 ;
                     OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Colombia" ;
                     OpenPVSignal:refers_to_database "WHO Vigibase" ;
                     rdfs:label "reports from Colombia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsFromFrance
:reportsFromFrance rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Reports_group ;
                   OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                   OpenPVSignal:has_count 8 ;
                   OpenPVSignal:refers_to_country "http://dbpedia.org/resource/France" ;
                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                   rdfs:label "reports from France" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsFromGermany
:reportsFromGermany rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Reports_group ;
                    OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                    OpenPVSignal:has_count 4 ;
                    OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Germany" ;
                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                    rdfs:label "reports from Germany" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsFromItaly
:reportsFromItaly rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Reports_group ;
                  OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                  OpenPVSignal:has_count 1 ;
                  OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Italy" ;
                  OpenPVSignal:refers_to_database "WHO Vigibase" ;
                  rdfs:label "reports from Italy" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsFromNetherlands
:reportsFromNetherlands rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Reports_group ;
                        OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                        OpenPVSignal:has_count 1 ;
                        OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Netherlands" ;
                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                        rdfs:label "reports from Netherlands" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsFromNorway
:reportsFromNorway rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Reports_group ;
                   OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                   OpenPVSignal:has_count 1 ;
                   OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Norway" ;
                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                   rdfs:label "reports from Norway" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsFromTurkey
:reportsFromTurkey rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Reports_group ;
                   OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                   OpenPVSignal:has_count 1 ;
                   OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Turkey" ;
                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                   rdfs:label "reports from Turkey" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsFromUnitedKingdom
:reportsFromUnitedKingdom rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Reports_group ;
                          OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                          OpenPVSignal:has_count 1 ;
                          OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_Kingdom" ;
                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                          rdfs:label "reports from United Kingdom" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsFromUnitedStates
:reportsFromUnitedStates rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Reports_group ;
                         OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                         OpenPVSignal:has_count 9 ;
                         OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_States" ;
                         OpenPVSignal:refers_to_database "WHO Vigibase" ;
                         rdfs:label "reports from United States" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsLackingCausality
:reportsLackingCausality rdf:type owl:NamedIndividual ,
                                  obo:OAE_0001182 ;
                         OpenPVSignal:has_content "The remaining six cases (not shown in Table 1) lacked sufficient evidence to suggest a causal relationship between vemurafenib and thrombocytopenia. In Case 8, the patient received radiation therapy to the lumbar vertebrae one day prior to starting treatment with vemurafenib and the thrombocytopenia improved while treatment with vemurafenib continued; in Cases 9 and 16, the thrombocytopenia appears to have preceded treatment with vemurafenib, and in Cases 25, 29 and 30, the temporal relationship to other medicines provides a more plausible alternative explanation for the thrombocytopenia. Causality could not be assessed for the remaining three cases (Cases1, 4 and 10) due to a lack of information in the reports." ;
                         rdfs:label "reports lacking causality" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithDechallengeStatusDoseNotChanged
:reportsWithDechallengeStatusDoseNotChanged rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Reports_group ;
                                            OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                            OpenPVSignal:has_count 2 ;
                                            OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                            OpenPVSignal:refers_to_dechallenge_process "false"^^xsd:boolean ;
                                            OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                                            rdfs:label "reports with dechallenge status dose not changed_ unknown outcome" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithDechallengeStatusDoseNotchanged_ThrombocytopeniaPersisting
:reportsWithDechallengeStatusDoseNotchanged_ThrombocytopeniaPersisting rdf:type owl:NamedIndividual ,
                                                                                OpenPVSignal:Reports_group ;
                                                                       OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                                                       OpenPVSignal:has_count 2 ;
                                                                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                       OpenPVSignal:refers_to_dechallenge_process "false"^^xsd:boolean ;
                                                                       OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
                                                                       rdfs:label "reports with dechallenge status dose not changed_ thrombocytopenia persisting" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithDechallengeStatusDoseNotchanged_ThrombocytopeniaResolving
:reportsWithDechallengeStatusDoseNotchanged_ThrombocytopeniaResolving rdf:type owl:NamedIndividual ,
                                                                               OpenPVSignal:Reports_group ;
                                                                      OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                                                      OpenPVSignal:has_count 2 ;
                                                                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                                      OpenPVSignal:refers_to_outcome_after_action "recovery without drug withdrawal" ;
                                                                      rdfs:label "reports with dechallenge status dose not changed_ thrombocytopenia resolving" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithFatalOutcome
:reportsWithFatalOutcome rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Reports_group ;
                         OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                         OpenPVSignal:has_count 3 ;
                         OpenPVSignal:refers_to_database "WHO Vigibase" ;
                         OpenPVSignal:refers_to_outcome_after_action "death" ;
                         rdfs:label "reports with fatal outcome" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithNegativeDechallenge
:reportsWithNegativeDechallenge rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                OpenPVSignal:has_count 1 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                OpenPVSignal:refers_to_dechallenge_outcome "negative - condition still applied" ;
                                rdfs:label "reports with negative dechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithNotRecovered
:reportsWithNotRecovered rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Reports_group ;
                         OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                         OpenPVSignal:has_count 6 ;
                         OpenPVSignal:refers_to_database "WHO Vigibase" ;
                         OpenPVSignal:refers_to_outcome_after_action "no recovery" ;
                         rdfs:label "reports with not recovered" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithPositiveDechallenge
:reportsWithPositiveDechallenge rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                OpenPVSignal:has_count 8 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                OpenPVSignal:refers_to_dechallenge_outcome "positive - condition not applied" ;
                                rdfs:label "reports with positive dechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithRecoveredAsOutcome
:reportsWithRecoveredAsOutcome rdf:type owl:NamedIndividual ,
                                        OpenPVSignal:Reports_group ;
                               OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                               OpenPVSignal:has_count 7 ;
                               OpenPVSignal:refers_to_database "WHO Vigibase" ;
                               OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                               rdfs:label "reports with recovered as outcome" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithRecoveringAsOutcome
:reportsWithRecoveringAsOutcome rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Reports_group ;
                                OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                OpenPVSignal:has_count 4 ;
                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                OpenPVSignal:refers_to_outcome_after_action "recovering" ;
                                rdfs:label "reports with recovering as outcome" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithSeriousOutcome
:reportsWithSeriousOutcome rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Reports_group ;
                           OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                           OpenPVSignal:has_count 23 ;
                           OpenPVSignal:refers_to_database "WHO Vigibase" ;
                           rdfs:label "reports with serious outcome" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithUnknownOutcome
:reportsWithUnknownOutcome rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Reports_group ;
                           OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                           OpenPVSignal:has_count 9 ;
                           OpenPVSignal:refers_to_database "WHO Vigibase" ;
                           OpenPVSignal:refers_to_outcome_after_action "unknown" ;
                           rdfs:label "reports with unknown outcome" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithUnknownOutcomeInDechallenge
:reportsWithUnknownOutcomeInDechallenge rdf:type owl:NamedIndividual ,
                                                 OpenPVSignal:Reports_group ;
                                        OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                        OpenPVSignal:has_count 3 ;
                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                        OpenPVSignal:refers_to_dechallenge_outcome "unknown" ;
                                        rdfs:label "reports with unknown outcome in dechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithVemurafenibAsTheOnlySuspectDrug
:reportsWithVemurafenibAsTheOnlySuspectDrug rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Reports_group ;
                                            OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                            OpenPVSignal:refers_to_primary_suspect_drug :vemurafenib ;
                                            OpenPVSignal:has_count 21 ;
                                            OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                            rdfs:label "reports with vemurafenib as the only suspect drug" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareportsWithVemurafenibTheOnlyDrug
:reportsWithVemurafenibTheOnlyDrug rdf:type owl:NamedIndividual ,
                                            OpenPVSignal:Reports_group ;
                                   OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                   OpenPVSignal:has_count 14 ;
                                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                   rdfs:label "reports with vemurafenib the only drug" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_age_info
:reports_with_age_info rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Reports_group ;
                       OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                       OpenPVSignal:has_count 24 ;
                       OpenPVSignal:has_max_age 70 ;
                       OpenPVSignal:has_median_age "56.5"^^xsd:float ;
                       OpenPVSignal:has_min_age 37 ;
                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                       rdfs:label "reports with age info" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_colorectal_cancer_as_indication
:reports_with_colorectal_cancer_as_indication rdf:type owl:NamedIndividual ,
                                                       OpenPVSignal:Reports_group ;
                                              OpenPVSignal:concerns_indication_for_use :colorectal_cancer ;
                                              OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                              OpenPVSignal:has_count 1 ;
                                              OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                              rdfs:label "reports with colorectal cancer as indication" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_dose_info
:reports_with_dose_info rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Reports_group ;
                        OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                        OpenPVSignal:refers_to_dosage :medianDosage ;
                        OpenPVSignal:has_count 14 ;
                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                        rdfs:label "reports with dose info" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_evaluation_certain
:reports_with_evaluation_certain rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Reports_group ;
                                 OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                 OpenPVSignal:has_count 1 ;
                                 OpenPVSignal:has_evaluation "Certain" ;
                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                 rdfs:label "reports with evaluation certain" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_evaluation_possible
:reports_with_evaluation_possible rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Reports_group ;
                                  OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                  OpenPVSignal:has_count 14 ;
                                  OpenPVSignal:has_evaluation "Possible" ;
                                  OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                  rdfs:label "reports with evaluation possible" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_evaluation_probable
:reports_with_evaluation_probable rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Reports_group ;
                                  OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                  OpenPVSignal:has_count 4 ;
                                  OpenPVSignal:has_evaluation "Probable" ;
                                  OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                  rdfs:label "reports with evaluation probable" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_hairy_cell_leukaemia_as_indication
:reports_with_hairy_cell_leukaemia_as_indication rdf:type owl:NamedIndividual ,
                                                          OpenPVSignal:Reports_group ;
                                                 OpenPVSignal:concerns_indication_for_use :hairyCellLeukemia ;
                                                 OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                                 OpenPVSignal:has_count 1 ;
                                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                 rdfs:label "reports with hairy cell leukaemia as indication" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_malignant_melanoma_as_indication
:reports_with_malignant_melanoma_as_indication rdf:type owl:NamedIndividual ,
                                                        OpenPVSignal:Reports_group ;
                                               OpenPVSignal:concerns_indication_for_use :melanoma ;
                                               OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                               OpenPVSignal:has_count 21 ;
                                               OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                               rdfs:label "reports with malignant melanoma as indication" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_negative_rechallenge
:reports_with_negative_rechallenge rdf:type owl:NamedIndividual ,
                                            OpenPVSignal:Reports_group ;
                                   OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                   OpenPVSignal:has_count 2 ;
                                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                   OpenPVSignal:refers_to_rechallenge_outcome "negative rechallenge - condition not appeared" ;
                                   rdfs:label "reports with negative rechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_partial_dechallenge
:reports_with_partial_dechallenge rdf:type owl:NamedIndividual ,
                                           OpenPVSignal:Reports_group ;
                                  OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                  OpenPVSignal:has_count 1 ;
                                  OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                  OpenPVSignal:refers_to_partial_dechallenge_outcome "unknown" ;
                                  rdfs:label "reports with partial dechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_positive_rechallenge
:reports_with_positive_rechallenge rdf:type owl:NamedIndividual ,
                                            OpenPVSignal:Reports_group ;
                                   OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                   OpenPVSignal:has_count 1 ;
                                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                   OpenPVSignal:refers_to_rechallenge_outcome "positive rechallenge - condition appeared again" ;
                                   rdfs:label "reports with positive rechallenge" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniareports_with_time_to_onset_info
:reports_with_time_to_onset_info rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Reports_group ;
                                 OpenPVSignal:is_subgroup_of :overallReportsInVigibase ;
                                 OpenPVSignal:time_to_onset :medianTimeToOnset ;
                                 OpenPVSignal:has_count 12 ;
                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                 rdfs:label "reports with time to onset info" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniarespiratoryInsufficiency
:respiratoryInsufficiency rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_MedDRA_code 10038695 ;
                          OpenPVSignal:has_MedDRA_prefered_term "Respiratory failure" ;
                          rdfs:label "respiratory insufficiency" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniarituximab
:rituximab rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "L01XC02" ;
           rdfs:label "rituximab" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniasalbutamol
:salbutamol rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "R03AC02" ;
            rdfs:label "salbutamol" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniasevelamer
:sevelamer rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "V03AE02" ;
           rdfs:label "sevelamer" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniasimvastatin
:simvastatin rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "C10AA01" ;
             rdfs:label "simvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaskinHaemorrhage
:skinHaemorrhage rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_MedDRA_code 10064265 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Skin haemorrhage" ;
                 rdfs:label "skin haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniasodiumBicarbonate
:sodiumBicarbonate rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Drug ;
                   OpenPVSignal:has_ATC_code "B05CB04 " ;
                   rdfs:label "sodium bicarbonate" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniasodiumPolystyreneSulfonate
:sodiumPolystyreneSulfonate rdf:type owl:NamedIndividual ,
                                     OpenPVSignal:Drug ;
                            OpenPVSignal:has_ATC_code "V03AE01 " ;
                            rdfs:label "sodium polystyrene sulfonate" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniasoftTissueHaemorrhage
:softTissueHaemorrhage rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_MedDRA_code 10051297 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Soft tissue haemorrhage" ;
                       rdfs:label "soft tissue haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaspironolactone
:spironolactone rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "C03DA01" ,
                                          "C03DA01 " ;
                rdfs:label "spironolactone" ,
                           "spironolactone " .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniatachycardiaVentricular
:tachycardiaVentricular rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_MedDRA_code 10047302 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Ventricular tachycardia" ;
                        rdfs:label "tachycardia ventricular" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniathrombocytopenia
:thrombocytopenia rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:refers_to_adverse_effect :ecchymoses ,
                                                        :epistaxis ,
                                                        :gastrointestinalBleeding ,
                                                        :gingivalBleed ,
                                                        :intracranialHemorrhage ,
                                                        :menorrhagia ,
                                                        :petechiae ;
                  OpenPVSignal:has_MedDRA_code 10043554 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Thrombocytopenia" ;
                  rdfs:label "thrombocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniatigecycline
:tigecycline rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "J01AA12" ;
             rdfs:label "tigecycline" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniatimolol
:timolol rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug ;
         OpenPVSignal:has_ATC_code "C07AA06 " ;
         rdfs:label "timolol" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniatobramycin
:tobramycin rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "J01GB01 " ;
            rdfs:label "tobramycin" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniaurinaryTractInfection
:urinaryTractInfection rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_MedDRA_code 10046571 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Urinary tract infection" ;
                       rdfs:label "urinary tract infection" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniausage_of_vemurafenib
:usage_of_vemurafenib rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Drug_Usage ;
                      OpenPVSignal:concerns_indication_for_use :brafv600eMutationPositive ,
                                                               :melanoma ;
                      OpenPVSignal:refers_to_dosage :recommendedDoseForVemurafenib ;
                      OpenPVSignal:refers_to_drug :vemurafenib ;
                      rdfs:label "usage of vemurafenib" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniavalproic_acid
:valproic_acid rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "N03AG01" ;
               rdfs:label "valproic acid" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniavemurafenib
:vemurafenib rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_mechanism :MechanismOfVemurafenib ,
                                        :PossibleMechanismOfVemurafenibInducingThrombocytopenia ;
             OpenPVSignal:has_ATC_code "L01XE15" ;
             rdfs:label "vemurafenib" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniavenipunctureSiteHaemorrhage
:venipunctureSiteHaemorrhage rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Adverse_Effect ;
                             OpenPVSignal:has_MedDRA_code 10054092 ;
                             OpenPVSignal:has_MedDRA_prefered_term "Vessel puncture site haemorrhage" ;
                             rdfs:label "venipuncture site haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniawhiteBloodCountDecreased
:whiteBloodCountDecreased rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_MedDRA_code 10047942 ;
                          OpenPVSignal:has_MedDRA_prefered_term "White blood cell count decreased" ;
                          rdfs:label "white blood count decreased" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopeniazolendronicAcid
:zolendronicAcid rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Drug ;
                 OpenPVSignal:has_ATC_code "M05BA08 " ;
                 rdfs:label "zolendronic acid" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#12HoursIntervalBetweenAdministrations
<http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#12HoursIntervalBetweenAdministrations> rdf:type owl:NamedIndividual ,
                                                                                                                          time:DurationDescription ;
                                                                                                                 time:nominalPosition "months" ;
                                                                                                                 time:numericPosition 12 ;
                                                                                                                 rdfs:label "12 hours interval between administrations" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#piperacillin/tazobactam
<http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#piperacillin/tazobactam> rdf:type owl:NamedIndividual ,
                                                                                                            OpenPVSignal:Drug ;
                                                                                                   OpenPVSignal:has_ATC_code "J01CR05" ;
                                                                                                   rdfs:label "piperacillin/tazobactam" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#saffeine/paracetemol/papaverSomniferumLatex
<http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#saffeine/paracetemol/papaverSomniferumLatex> rdf:type owl:NamedIndividual ,
                                                                                                                                OpenPVSignal:Drug ;
                                                                                                                       rdfs:label "saffeine/paracetemol/papaver somniferum latex" .


###  http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#sulfamethoxazole/trimethoprim
<http://purl.org/OpenPVSignal/Signals/2015_3_vemurafenib_thrombocytopenia#sulfamethoxazole/trimethoprim> rdf:type owl:NamedIndividual ,
                                                                                                                  OpenPVSignal:Drug ;
                                                                                                         OpenPVSignal:has_ATC_code "J01EE01" ;
                                                                                                         rdfs:label "sulfamethoxazole/trimethoprim" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
